biostudies-literatureUnknown12Daenen K<h4>Background</h4>In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19.<h4>Objective</h4>Our goal is to determine the most optimal dosing and tiJMIR research protocolse48183https://www.ebi.ac.uk/biostudies/studies/S-EPMC10276318biostudies-literatureOptimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT).PMC10276318Bogerd MSchinkel JPillay Jvan Wijk Bde Graaff MJvan Welie LKuiper MAvan Oosten PVeldhuis LIvan der Ven WHvan der Ven FLJuffermans NPRoozeman JPBergmans DCSpronk PEAydeniz EAlgera AGBreel JSHorn Jden Boer SKucukcelebi SSleeswijk MEvan de Berg Pvan der Horst Rvan Zanten ARAhuja SIe ELDaenen KNijbroek SGTri ABuiteman-Kruizinga LAHol Lvan der Woude Mvan Meenen DMYaali NMazzinari Gvan Velzen PDi Leo VVoorham JJRettig TCDGalekaldridge MSWong WYPRoVENT- and PRoAcT-COVID Collaborative GroupSciascera AAde Boer MMVerhoef EJvan Gorp ECMDijk JVKuipers LJvan den Bersselaar DIElting LMDetermann RMBruna CLvan Akkeren JPvan Ingen LEKho EDelmte MCoene WTsonas AMCremer OKant MBos LDJGoossen RLSerpa Neto ASivakorn CZonneveld SAKoopman AWSchavemaker Nvan Amstel RBde Lange DWVerboom MRettig TCOffermans MPennartz CJBevers Mden Uil CAHansen HJMartin–Loeches IRezaee ASvan der Heiden PLStilma WVermeulen TDBindels AJMyatra SDongelmans DASwart PEndeman HKoornstra Evan Vliet PHagens LASchultz MJIvanov DBoers LSHaringman JJOostdijk EAValk CMAShrestha GWinters TGommers DAMPJde Bruin HRosenberg NMGirbes ARBoyd AAlgoe CKvan Meenen DMPHoeijmakers LLvan der Voort PWeinerGo DMDieperink WTuinman PRZandvliet JMMoeniralam HSPurmer IMPisters TBos LDvan Willigen HVlaar APPaulus FBaur OLvan Zijl TZDalm VASHRoca ODormans TPShrestha GSPrins ABotta Mvan Mourik NLokhorst Avan der Voort PHHuijben JAStoof SCMEsmeijer AAValkenburg AJGama de Abreu MBertens FAvan der Heide STde Klerk ESHollmann MWStrang ACKoopmans MMartin-Loeches IfalseOptimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT).<h4>Background</h4>In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19.<h4>Objective</h4>Our goal is to determine the most optimal dosing and ti2023-01-01T00:00:00Z2023 Jun2026-05-28T14:19:50.828Z2024-11-20T03:04:10.692ZS-EPMC102763183726699310.2196/48183